This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the annual probability of having a complication following SCS; the annual probability of failing SCS from year 2 onwards; the probability of achieving satisfactory pain relief with SCS in the first 2 years post-implant; the annual decrement in annual probability of achieving satisfactory pain relief with SCS from year 2 onwards; the probability of achieving satisfactory pain relief with CMM in the first 2 years of receiving treatment; the annual probability of having a complication following CMM; and the annual decrement in annual probability of achieving satisfactory pain relief with CMM from year 2 onwards.
Battery life of the SCS implant was also assessed.
Study designs and other criteria for inclusion in the review
The authors searched for clinical effectiveness estimates derived from randomised controlled trials (RCTs), or systematic review evidence.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
The authors found only one RCT of SCS. This randomised FBSS patients to either SCS or re-operation (Taylor et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic details). The authors appear to have chosen another RCT in their indirect comparison, which was based on length of follow-up over 2 years (FBSS patients randomised to either CMM or re-operation). No justification was provided for the choice of study supplying long-term complication and pain relief data for SCS; the implication was that only one study existed.
Number of primary studies included
The authors reported that three primary studies or references, along with a personal communication from the authors of one of the studies (Kumar et al. 2002) in 2003, provided the effectiveness evidence.
Methods of combining primary studies
The studies were not combined.
Investigation of differences between primary studies
The authors did not investigate any differences between the primary studies, or how these differences affected the estimate of the effectiveness of the technology. They appear to have been restricted by the low number of available studies for inclusion.
The annual probability of having a complication following SCS was 0.18.
The annual probability of failing SCS from year 2 onwards was 0.02. The probability of achieving satisfactory pain relief with SCS in the first 2 years post-implant was 0.474.
The annual decrement in annual probability of achieving satisfactory pain relief with SCS from year 2 onwards was 0.06. The probability of achieving satisfactory pain relief with CMM in the first 2 years of receiving treatment was 0.0583.
The annual probability of having a complication following CMM was set to zero in the absence of data.
The annual decrement in annual probability of achieving satisfactory pain relief with CMM from year 2 onwards was also set to zero in the absence of data.
The battery life of the SCS implant was 4 years.
Measure of benefits used in the economic analysis
Quality-adjusted life-years (QALYs) were used in the economic analysis. The utility estimates in patients with FBSS could not be found, so utilities reported in the Beaver Dam study (Fryback et al. 1993 , see 'Other Publications of Related Interest' below for bibliographic details) were used. These focused on patients who reported an "episode of severe back pain" in the past 12 months. Patient utility associated with satisfactory and unsatisfactory pain outcomes was imputed, along with the utility loss associated with an SCS-related complication, based on a method adapted from Malter et al. 1996 (see 'Other Publications of Related Interest' below for bibliographic details).
Direct costs
One single-study Canadian study (Kumar et al. 2002) was identified as having undertaken a comprehensive examination of health care costs associated with SCS and CMM in FBSS patients. The patterns of health care resource use and costs were considered reflective of European clinical practice. These were directly used in the model following agreement from a clinical advisory panel. Costs, but not quantities, were reported for SCS implantation and year 1 costs, SCS complications, SCS reimplantation, annual maintenance costs of SCS from year 2 onwards, CMM in year 1, and annual maintenance costs of CMM from year 2 onwards. The costs were reflated, using EU-15 health care price inflation rates, to 2003 prices. Discounting was not applied although it was relevant over a lifetime analysis.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not included.
Currency
Euros (Euro). Prices were converted from Canadian dollars (Can$) based on purchasing power parity, but the precise rate was not reported.
Sensitivity analysis
The authors aimed to examine the effect of data limitations in the assessment of SCS efficacy and long-term disease process. One-way sensitivity analyses were conducted. The parameters investigated were the SCS screening, complication and failure rates, SCS effectiveness, CMM complication rate, SCS screening pass rate, battery life and life expectancy. Most ranges were assumptions, but alternative SCS effectiveness data was drawn from a case series
